The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma.
Liver cancer is a common cancer and a leading cause of cancer-related deaths. Among all types of primary liver cancers, hepatocellular carcinoma (HCC) is the major histological subtype, and hepatitis B virus (HBV) infection is the leading cause of HCC. Treatments for hepatitis B related HCC include hepatectomy, liver transplantation, transarterial chemoembolization (TACE), ablative therapy, and Sorafenib treatment. However, HBV reactivation can occur in patients who receive these treatments, resulting in poor clinical outcomes. However, prophylactic antiviral treatment in patients with hepatitis B-related HCC, can reduce the copies of HBV DNA, prevent HBV reactivation, reduce hepatic inflammation, reverse liver fibrosis, decrease tumor recurrence and metastasis, and extend survival time. Prophylactic antiviral treatment should be routinely performed as an important adjuvant therapy in HBV-related HCC patients.
Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Enze
E
Jiang
Weinberg College of Arts and Sciences, Northwestern University, Evanston, IL, USA.
Anna Junjie
AJ
Shangguan
Department of Medical Oncology, Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China.
Shuangshuang
S
Chen
Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Lin
L
Tang
Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Shuang
S
Zhao
Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China. Electronic address: 13327800182@189.cn.
Zhenghong
Z
Yu
D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000628:therapy* / Q000821:virology; D018450:Disease Progression; D004334:Drug Administration Schedule; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D006509:Hepatitis B / Q000175:diagnosis / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000628:therapy* / Q000821:virology; D012008:Recurrence; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014775:Virus Activation / Q000187:drug effects*
D000998:Antiviral Agents
Antiviral treatment; Hepatitis B virus; Hepatocellular carcinoma